FGFR1 and glioma: Given the disparities between DMG_K27-BRAF/FGFR1 and classical DMG H3K27-altered, we hypothesised that DMG H3 K27-altered with MAPK-activating mutations might correspond to either (i) a new subtype of DMG or (ii) atypical aggressive MAPK-driven low-grade gliomas/glioneuronal tumours.